Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumours in adults. Lancet. 2003;361:323–31.

PubMed  Google Scholar 

Cruz Da Silva E, Mercier MC, Etienne-Selloum N, Dontenwill M, Choulier L. A systematic review of glioblastoma-targeted therapies in phases II, III, IV clinical trials. Cancers (Basel). 2021;13:1795.

PubMed  Google Scholar 

Robertson T, Koszyca B, Gonzales M. Overview and recent advances in neuropathology. Part 1: central nervous system tumours. Pathology. 2011;43:88–92.

PubMed  Google Scholar 

Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.

CAS  PubMed  Google Scholar 

Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003.

CAS  PubMed  Google Scholar 

Miranda A, Blanco-Prieto M, Sousa J, Pais A, Vitorino C. Breaching barriers in glioblastoma. Part I: molecular pathways and novel treatment approaches. Int J Pharm. 2017;531:372–88.

CAS  PubMed  Google Scholar 

Jiapaer S, Furuta T, Tanaka S, Kitabayashi T, Nakada M. Potential strategies overcoming the temozolomide resistance for glioblastoma. Neurol Med Chir (Tokyo). 2018;58:405–21.

PubMed  Google Scholar 

Sulli G, Lam MTY, Panda S. Interplay between circadian clock and cancer: new frontiers for cancer treatment. Trends Cancer. 2019;5:475–94.

CAS  PubMed  PubMed Central  Google Scholar 

Nelson N, Relogio A. Molecular mechanisms of tumour development in glioblastoma: an emerging role for the circadian clock. NPJ Precis Oncol. 2024;8:40.

PubMed  PubMed Central  Google Scholar 

Masri S, Sassone-Corsi P. The emerging link between cancer, metabolism, and circadian rhythms. Nat Med. 2018;24:1795–803.

CAS  PubMed  PubMed Central  Google Scholar 

Yu L, Chen Y, Tooze SA. Autophagy pathway: cellular and molecular mechanisms. Autophagy. 2018;14:207–15.

CAS  PubMed  Google Scholar 

Cuomo F, Altucci L, Cobellis G. Autophagy function and dysfunction: potential drugs as anti-cancer therapy. Cancers (Basel). 2019;11:1465.

CAS  PubMed  Google Scholar 

Li C, Liu Y, Liu H, et al. Impact of autophagy inhibition at different stages on cytotoxic effect of autophagy inducer in glioblastoma cells. Cell Physiol Biochem. 2015;35:1303–16.

CAS  PubMed  Google Scholar 

Liu T, Zhang J, Li K, Deng L, Wang H. Combination of an autophagy inducer and an autophagy inhibitor: a smarter strategy emerging in cancer therapy. Front Pharmacol. 2020;11:408.

CAS  PubMed  PubMed Central  Google Scholar 

Taylor MA, Das BC, Ray SK. Targeting autophagy for combating chemoresistance and radioresistance in glioblastoma. Apoptosis. 2018;23:563–75.

CAS  PubMed  PubMed Central  Google Scholar 

Gonzalez-Aponte MF, Damato AR, Trebucq LL, et al. Circadian regulation of MGMT expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastoma. J Neurooncol. 2024;166:419–30.

CAS  PubMed  PubMed Central  Google Scholar 

Wagner PM, Sosa Alderete LG, Gorne LD, et al. Proliferative glioblastoma cancer cells exhibit persisting temporal control of metabolism and display differential temporal drug susceptibility in chemotherapy. Mol Neurobiol. 2019;56:1276–92.

CAS  PubMed  Google Scholar 

Wagner PM, Monjes NM, Guido ME. Chemotherapeutic effect of SR9009, a REV-ERB agonist, on the human glioblastoma T98G cells. ASN Neuro. 2019;11:1759091419892713.

CAS  PubMed  PubMed Central  Google Scholar 

Wagner PM, Fornasier SJ, Guido ME. Pharmacological modulation of the cytosolic oscillator affects glioblastoma cell biology. Cell Mol Neurobiol. 2024;44:51.

CAS  PubMed  PubMed Central  Google Scholar 

Wagner PM, Prucca CG, Velazquez FN, Sosa Alderete LG, Caputto BL, Guido ME. Temporal regulation of tumor growth in nocturnal mammals: in vivo studies and chemotherapeutical potential. FASEB J. 2021;35: e21231.

CAS  PubMed  Google Scholar 

Lee SY. Temozolomide resistance in glioblastoma multiforme. Genes Dis. 2016;3:198–210.

PubMed  PubMed Central  Google Scholar 

Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol. 2002;20:2388–99.

CAS  PubMed  Google Scholar 

Dong Z, Zhang G, Qu M, et al. Targeting glioblastoma stem cells through disruption of the circadian clock. Cancer Discov. 2019;9:1556–73.

CAS  PubMed  PubMed Central  Google Scholar 

Altman BJ. Cancer clocks out for lunch: disruption of circadian rhythm and metabolic oscillation in cancer. Front Cell Dev Biol. 2016;4:62.

PubMed  PubMed Central  Google Scholar 

Elshazly AM, Gewirtz DA. Is autophagy inhibition in combination with temozolomide a therapeutically viable strategy? Cells. 2023;12:535.

CAS  PubMed  PubMed Central  Google Scholar 

Singh N, Miner A, Hennis L, Mittal S. Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review. Cancer Drug Resist. 2021;4:17–43.

CAS  PubMed  PubMed Central  Google Scholar 

Huang G, Zhang F, Ye Q, Wang H. The circadian clock regulates autophagy directly through the nuclear hormone receptor Nr1d1/Rev-erbalpha and indirectly via Cebpb/(C/ebpbeta) in zebrafish. Autophagy. 2016;12:1292–309.

CAS  PubMed  PubMed Central  Google Scholar